Janssen has announced a new collaboration with the Chinese healthcare company Legend Biotech, which aims to develop a new treatment for cancer.

The worldwide collaboration and licence agreement will focus on the development, manufacturing and commercialisation of a chimeric antigen receptor T-cell (CAR-T) drug candidate, LCAR-B38M, which is currently being assessed as a therapy for multiple myeloma.

“Janssen is partnering with Legend Biotech to develop an investigational CAR-T anticancer therapy.“

LCAR-B38M works by specifically targeting the B-cell maturation antigen and has already been accepted for review by the China Food and Drug Administration, with clinical studies for multiple myeloma currently in the planning phase in the US.

Under terms of the agreement, Legend will grant Janssen a worldwide licence to jointly develop and commercialise LCAR-B38M in multiple myeloma alongside Legend's team, with Janssen recording worldwide net trade sales, excepting those made in Greater China.

Dr Mathai Mammen, global head of science and development for Janssen Research and Development, said: "We are excited to bring Janssen's global expertise in drug development to advance this innovation into potential new treatment options for patients around the world."

With over 20 years of experience within the pharmaceutical market, we at Zenopa have the knowledge, skills and expertise to help find the right job for you. To find out more about the current pharmaceutical roles we have available, you can search for the latest job roles, register your details, or contact the team today.